IL2RA and Hodgkins lymphoma: Ongoing clinical trials of CD25 antibodies include 90Yttrium–basiliximab plus BEAM prior to auto-HCT in HL ([103], phase II, recruiting) and 90Yttrium–basiliximab plus BEAM prior to auto-HCT in T cell NHL ([104], phase I, active).